Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (REPL)
NASDAQ:REPL
REPL Stock Chart & Stats
$9.69
$0.17(1.56%)
At close: 4:00 PM EST
$9.69
$0.17(1.56%)
Day’s Range― - ―
52-Week Range$2.68 - $14.80
Previous CloseN/A
Volume95.41K
Average Volume (3M)1.83M
Market Cap
$757.76M
Enterprise Value$137.81M
Total Cash (Recent Filing)$323.64M
Total Debt (Recent Filing)$76.32M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding78,443,340
10 Day Avg. Volume1,454,926
30 Day Avg. Volume1,828,199
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.89
Price to Sales (P/S)0.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-162.51
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$11.43Price Target Upside17.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessIGNYTE trial results support approval with an objective response rate of 33.6%, which is significantly higher than expected with anti-PD1 agents alone.
Market ConfidenceAnalyst's recommendation to upgrade the stock to OP reflects renewed confidence following the FDA's acceptance and management's expressed confidence in the path forward.
Regulatory ApprovalThe FDA has accepted the resubmission of the Biologics License Application for RP1 + Opdivo for review, indicating progress towards potential approval.
Bears Say
Prolonged Approval PathThere is a prolonged path to approval for RP1, as Replimune will likely have to run another trial to garner approval in the U.S.
Regulatory UncertaintyUncertainty remains until there is an approval, as regulatory probability of success is difficult to predict at this stage.
Skepticism On Clinical DataThere remains skepticism on the clinical data from the single-arm IGNYTE trial as the basis for accelerated approval.
Replimune Group News
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $2.68 and its highest was $14.79 in the past 12 months.
What is Replimune Group Inc’s market cap?
Replimune Group Inc’s market cap is $757.76M.
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is May 14, 2026 which is in 145 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on Nov 06, 2025. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.74 by -$0.16.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 78,443,340 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.74. Following the earnings report the stock price went down -0.932%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.43 (17.96% Upside)
$11.43 (17.96% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $146.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.89%
12-Months-Change
Fundamentals
Return on Equity
-96.24%
Trailing 12-Months
Asset Growth
-21.83%
Trailing 12-Months
Company Description
Replimune Group Inc
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$11.43
▲(17.96% Upside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
Currently, No data available
---